Replies to post #22450 on Cytodyn Inc (CYDY)

[finesand]

chump- thank you & this may show what's wrong
with the overall situation of Pro 140 and the public perception.

While being well reported in science journals, papers and 'insiders', it seems that these publicity soft science magazines simple love to dismiss Pro 140.

In this report it was not the 1st report, but IZ was - that's fine since it has been approved.
But then, I almost spilled my wine, fostemsavir has been mentioned as number 2. And .. before we close, let's mention this thing called Pro 140 (o8>

Daniel Kuritzkes, MD: There’s a third entry inhibitor, PRO-140, that is also an antibody. It blocks the other receptor for HIV, CCR5. It can be given by injection, subcutaneously. So, although it has to be given weekly, patients can self-administer it. It’s also being studied in potential salvage situations. The trick there, though, is that the virus can change the receptor that it uses. For many patients who have advanced disease, or have had a long history of treatment and many rounds of virologic failure, the virus will have changed to the form of virus that can’t be inhibited by PRO-140. So, we’ll have to see what the clinical trials show.

http://www.mdmag.com/peer-exchange/hiv-treatment-landscape/emerging-therapies-in-patients-with-virologic-resistance

And yes, they mumble about a potential change in co-receptor (to X4) tropism, which has been refuted by last years CROI poster and by the Berlin patient. See my post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140676706

So still, our CCR5 blocker needs more public validation and support. Slowly getting out of the 2016 negativity hole with PE data of pivotal trial. Maybe that shall make them change their minds about Pro 140 and the company.

Oh well .. not yet the top dog in the pharmacy yet (o8>